Jiangyang Chi

Jiangyang Chi


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
QWQingpeng Wang
Qingpeng Wang
JCJiangyang Chi
Jiangyang Chi
CWChen Wang
Chen Wang
YYYun Yang
Yun Yang
RTRui Tian
Rui Tian
XCXinzhong Chen
Xinzhong Chen
Objective: The aim of this study is to assess the association between epicardial adipose tissue (EAT) and coronary artery disease (CAD) via meta−analysis. Methods: Specific searches of online databases from January 2000 to May 2022 were conducted. All observational studies evaluating the association between EAT and CAD in PubMed, Web of Science, and the Cochrane Library databases were screened. A meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta−Analyses guidelines (PRISMA). In total, 21 studies encompassing 4975 subjects met the inclusion criteria, including 2377 diagnosed and assigned as the CAD group, while the other 2598 were assigned as the non−CAD group. Subjects in the CAD group were further divided into the severe stenosis group (stenosis ≥ 50%, n = 846) and the mild/moderate stenosis group (stenosis < 50%, n = 577). Results: Both the volume and thickness of EAT in the CAD group were larger compared to the non−CAD group (p < 0.00001). In a subgroup analysis within the CAD group, the severe stenosis group had a larger volume and thickness with respect to EAT when compared to the mild/moderate group (p < 0.001). Conclusions: The enlargement of EAT presented in CAD patients with an association with CAD severity. Although limited by different CAD types and measuring methods for EAT, as well as a smaller sample size, our results suggest that EAT is a novel predictor and a potential therapeutic target for CAD.

14 May 2024 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SLShuang Lin
Shuang Lin
HZHanxiao Zeng
Hanxiao Zeng
CWChenyang Wang
Chenyang Wang
ZCZixue Chai
Zixue Chai
XZXueke Zhang
Xueke Zhang
ZHZhengxi Hu
Zhengxi Hu

25 June 2024 in Phytochemistry
Verified
Journal Article
Closed access
SLShuang Lin
Shuang Lin
ZCZixue Chai
Zixue Chai
HZHanxiao Zeng
Hanxiao Zeng
BYBeiye Yang
Beiye Yang
JCJiangyang Chi
Jiangyang Chi
ZHZhengxi Hu
Zhengxi Hu

4 September 2025 in Current Medical Science
Verified
Journal Article
Closed access
PDF file
QWQing-Peng Wang
Qing-Peng Wang
CWChen Wang
Chen Wang
YYYan-Hong Yuan
Yan-Hong Yuan
YYYun Yang
Yun Yang
RTRui Tian
Rui Tian
XCXinzhong Chen
Xinzhong Chen

20 October 2025 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
RGRuikang Guo
Ruikang Guo
BGBingchuan Geng
Bingchuan Geng
WYWai Yen Yim
Wai Yen Yim
PZPeng Zhu
Peng Zhu
HZHongyan Zhang
Hongyan Zhang
JCJiangyang Chi
Jiangyang Chi

1 January 2026 in Targetome
Verified
Journal Article
Open access
PDF file
CSChenchen Sun
Chenchen Sun
XZXiangwang Zhao
Xiangwang Zhao
JCJiangyang Chi
Jiangyang Chi
YZYonghui Zhang
Yonghui Zhang
ZHZhengxi Hu
Zhengxi Hu
Although heart transplantation remains the definitive therapy for end-stage heart failure, its widespread application is constrained by conventional static cold storage (SCS), where prolonged cold ischemia inflicts irreversible injury. Current preservation solutions lack pharmacologically active components capable of targeting unique hypothermia-induced damage, including lipid phase separation, mitochondrial decay, and restricted succinate clearance, which collectively trigger a devastating oxidative stress burst upon reperfusion. To address this clinical bottleneck, this review systematically deciphers the pathophysiology of cold ischemic injury, framing the discussion around the metabolic distinctions between warm and cold ischemia. We synthesize pivotal molecular interventions targeting oxidative stress cascades, programmed cell death networks (such as apoptosis and ferroptosis), sterile inflammation, organelle impairment, and epigenetic dysregulation, while clarifying their specific applicable scenarios. Crucially, we evaluate the therapeutic superiority of natural products derived from plants, fungi, and marine animals as multi-target synergistic agents, while confronting translational barriers involving their low bioavailability and complex regulatory approval. Ultimately, we outline actionable paradigms to bridge this translational gap, highlighting nanocarrier-based advanced drug delivery and the utilization of in vitro mechanical perfusion as an active therapeutic platform. Integrating these tools with multi-omics profiling allows for personalized, donor-specific preservation strategies. Together, this comprehensive review provides essential theoretical insight and practical guidance to optimize donor graft viability and advance the field of myocardial protection worldwide.